focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIxico Regulatory News (IXI)

Share Price Information for Ixico (IXI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 7.30
Bid: 7.25
Ask: 7.35
Change: 0.00 (0.00%)
Spread: 0.10 (1.379%)
Open: 7.30
High: 7.30
Low: 7.30
Prev. Close: 7.30
IXI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Appointment of Non-Exec

5 Jun 2006 07:00

Phytopharm PLC05 June 2006 Company Contact: U.K. Investor Relations Contact:Phytopharm plc Financial DynamicsDr Richard Dixey David Yates / Ben Atwell +44 207 831 3113+44 7867 782000Dr Daryl Rees+44 1480 437 697www.phytopharm.com Appointment of Non Executive Director GODMANCHESTER, Cambridgeshire, U.K. (June 5 2006) - Phytopharm plc (LSE: PYM;NASDAQBB: PHYOF; PHYOY) ("Phytopharm") announces the appointment with immediateeffect of Mr A D (Sandy) Morrison, former CEO of Lipton Ltd (a Unileversubsidiary) as a Non-executive Board Director of Phytopharm. Mr Morrison (aged 59) has a BSc (Hons) in applied chemistry (Strathclyde) andhas over 20 years experience in general and international management, globalsupply chain and R&D. He was Chief Executive Officer of Lipton Ltd, the globaltea sourcing organization for Unilever with operations in six countries for fiveyears from 2000 to 2006. During Mr Morrison's period as CEO, substantialoperational & financial improvements were made to the Unilever global tea supplychain and he also played a significant part in addressing issues in theinternational tea trade. In the immediate years prior to 2000, Mr Morrison hadsenior international food & beverage roles for Unilever outside the UK, in thesupply chain and in R&D, both at the Rotterdam head office and in the Unileverfood and beverage subsidiary in Australia. Commenting on the appointment, Mr Gordon Stevens, Chairman of Phytopharm, said;"the appointment of a person of this calibre and experience to the Board ofPhytopharm will provide an important asset to the Company and I am delightedthat Sandy will be joining us. This appointment begins a process ofrestructuring of the Board and I look forward to the announcement of furtherappointments in due course." There are no further details required to be disclosed under paragraph 9.6.13R ofthe Listing Rules or Disclosure Rule 3.1.2R. -ENDS- NOTES TO EDITORS Phytopharm plc Phytopharm is a pharmaceutical company with a plant extract division. Thepharmaceutical division is dedicated to the discovery and development of singlechemicals as prescription medicines and the plant extract division is focussedon the development of plant extracts as functional foods and veterinaryproducts.. More information concerning Phytopharm's activities can be found on its web site at http://www.phytopharm.com This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
7th May 20247:00 amRNSNotice of half year results
15th Apr 20247:00 amRNSLife Molecular Imaging – Neuraceq Supply Agreement
3rd Apr 20247:00 amRNSImeka Collaboration Agreement
13th Mar 20247:00 amRNSTrading Update
29th Jan 202412:00 pmRNSHolding(s) in Company
25th Jan 20244:00 pmRNSResult of AGM
12th Jan 20249:35 amRNSDirectorate Change
27th Dec 20237:00 amRNSUpdate regarding Nominated Adviser and Broker
15th Dec 20237:00 amRNSChange of Auditor
5th Dec 20237:00 amRNSFinancial Results for year ended 30 September 2023
27th Nov 20237:00 amRNSNotice of Results and Investor Presentation
5th Oct 20237:00 amRNSAppointment of Independent Non-Executive Director
29th Sep 20237:00 amRNSTrading Update
18th Jul 20237:00 amRNSContract Win
14th Jun 20237:00 amRNSContract Win
23rd May 20237:00 amRNSHalf year report
16th May 20237:00 amRNSInvestor Meet Company presentation
10th May 20237:00 amRNSTrading Update
3rd Apr 20238:35 amRNSExtension of Huntington's disease consortium
21st Mar 202312:11 pmRNSHolding(s) in Company
10th Mar 20237:00 amRNSContract Win
7th Feb 20237:00 amRNSTrading Update
31st Jan 20234:35 pmRNSPrice Monitoring Extension
31st Jan 20232:05 pmRNSSecond Price Monitoring Extn
31st Jan 20232:00 pmRNSPrice Monitoring Extension
31st Jan 202311:05 amRNSSecond Price Monitoring Extn
31st Jan 202311:00 amRNSPrice Monitoring Extension
27th Jan 20231:00 pmRNSResult of AGM
3rd Jan 20237:00 amRNSTotal Voting Rights
22nd Dec 202212:18 pmRNSDirector Bed & ISA Dealing
13th Dec 20227:00 amRNSPDMR Exercise of Options
9th Dec 20229:05 amRNSContract Win
8th Dec 20223:34 pmRNSContract Update
7th Dec 20227:00 amRNSFinancial Results for the year ended 30 Sept 2022
21st Nov 20227:00 amRNSNotice of Results and Investor Presentation
25th Oct 20227:00 amRNSTrading Update
21st Sep 202210:35 amRNSHD-IH Consortium
14th Sep 20227:00 amRNSGrant of Share Options
1st Sep 20227:00 amRNSTrading Update and FY2023 Guidance
4th Aug 20227:00 amRNSContract Win
26th Jul 202211:22 amRNSContract Win - Replacement
21st Jul 20227:00 amRNSContract Win
14th Jun 20227:00 amRNSContract Extension
24th May 20227:00 amRNSHalf-year Report and Trading Update
16th May 20227:00 amRNSInvestor Presentation
10th May 20227:00 amRNSConsortium Agreement in Huntington's Disease
25th Apr 20227:00 amRNSTrading Update
21st Apr 20227:00 amRNSNew Contract Win
8th Mar 20227:00 amRNSContract worth circa £800k
14th Feb 20227:00 amRNSLaunch of IXIQ.Ai Deep learning AI-based platform

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.